Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Our lead product, ANEB-001, has the potential to rapidly reverse the effects of acute cannabinoid intoxication, a relatively unknown yet serious affliction that sends more than 5,000 Americans to the hospital emergency department every day.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. OCT’s second programme uses inhaled phytocannabinoids to target an undisclosed orphan pain condition, with Phase 1 trials also scheduled for Q3 2022 and Phase 2 expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

PrestoDoctor

DECEMBER 12, 2023

Additionally, cannabis has shown promise in easing symptoms of chronic conditions such as arthritis, insomnia, and anxiety. Additionally, using cannabis for medical conditions does not mean THC must be consumed. CBD also plays an important role in management of conditions without the psychoactive high.

Medicine 98

Medicine Chronic Pain Consumption Pharmaceutical 98

Cannabis Law Report

JUNE 1, 2022

Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients. Our team in Europe is excited to join forces with new colleagues from Pharmadrug GmbH, with their valuable expertise in the German pharmaceutical market.”

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Cannabis Law Report

AUGUST 27, 2021

Nextleaf Solutions’s technologies are focused on transforming cannabis or hemp biomass to a standardized cannabinoid oil as efficiently as possible. It’s capable of extracting cannabinoids from cannabis biomass in a non-flammable and inexpensive co-solvent system using a flow-through ultrasonic extraction system. Flawless Strategy.

Extraction 98

Extraction Cannabinoids Research and Development Oil 98

United Patients Group

FEBRUARY 7, 2023

Inflammation can lead to a wide range of diseases and conditions, including heart disease, arthritis and cancer. This article will cover some common uses for medical cannabis when treating inflammation or pain along with what other ingredients might be helpful in reducing symptoms related to these conditions!

Cannabinoids 114

Cannabinoids Chronic Pain Terpenes THC 114

Cannabis Law Report

DECEMBER 1, 2021

Cannabis and Life Sciences Company Initiates Internal Study Comparing Anti-Inflammatory Properties of Candidate JUVA-019 When Combined With Cannabinoids Such as THC and CBD. who has an extensive background in pharmaceutical research and development. November 30, 2021 04:00 ET | Source: Juva Life Inc.

Cannabinoids 52

Cannabinoids Research and Development Pharmaceutical THC 52

Veriheal

JANUARY 26, 2023

Bipolar disorder is a complex condition that impacts millions worldwide, leading to extreme mood swings, intense emotional episodes, and difficulty managing day-to-day life. Most commonly, pharmaceutical medication is prescribed to regulate moods. But there may be some good news for those coping with this mental health issue.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. Chris Chapman, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

MMJ Recs

FEBRUARY 18, 2024

This comprehensive article aims to explore the myriad health benefits of medical marijuana, delving into its therapeutic potential, impact on mental health, role in managing chronic conditions, and the holistic healing it offers, with a special focus on cannabinoids like CBD.

Chronic Pain 52

Chronic Pain Marijuana Epilepsy Research and Development 52

Veriheal

APRIL 7, 2022

As with many other conditions, there is a lack of research regarding the use of MMJ as an alternative treatment to relieve symptoms of MS. . The researchers suggest that the cannabinoids in MMJ can assist with the treatment of MS, contributing “add-on immunosuppressive, analgesic, neuroprotective and remyelinative effects.”

Patients 98

Patients Treatment Cannabinoids Pharmaceutical 98

Cannabis Law Report

FEBRUARY 1, 2022

New softgel capsule products further expand ZYUS’ medical cannabinoid offerings and provide patients a precise method for dosing. The launch of these two new softgel products marks another important milestone in ZYUS’ mission to elevate cannabinoids as a standard of care and leverage their transformational potential.

Cannabinoids 52

Cannabinoids Patients Research and Development Media 52

Veriheal

AUGUST 9, 2023

Recent research reaffirms earlier studies that claim that certain non-marijuana plants contain similar compounds found in cannabis, often called cannabinoids. Even more, CBD is the first FDA-approved pharmaceutical drug for two rare forms of epileptic seizures in kids.

CBD 96

CBD Cannabinoids THC Extraction 96

Cannabis Law Report

NOVEMBER 17, 2021

Launch of Zylem ™ 20:1 further expands ZYUS product offerings with new cannabinoid formulation. The launch of this formulation marks an important milestone in ZYUS’ mission to elevate cannabinoids as a standard of care and leverage their transformational potential.

Cannabinoids 52

Cannabinoids Patients Research and Development Extraction 52

Veriheal

OCTOBER 13, 2020

Ulcerative Colitis is a condition that causes long-lasting inflammation and ulcers (sores) in the innermost lining of the individual’s large intestine and rectum. Crohn’s Disease is also a condition that causes inflammation, but it affects the lining of the digestive tract, which can then spread deeply into the affected tissues. .

Digestion 123

Digestion Treatment Conditions Research and Development 123

Cannabis Law Report

AUGUST 29, 2021

This export also validates the emergence of the global cannabinoid sector with reliance on quality, traceability and sustainability that Avicanna ’s Aureus products offer. To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

Extraction 98

Extraction Supply Chain Research and Development CBD 98

MMJ Recs

JANUARY 6, 2024

In recent years, the landscape of medical marijuana has evolved dramatically, offering patients a diverse array of products tailored to address a myriad of health conditions. Inhalable options , including vaporizers and pre-rolled joints, allow for rapid onset of effects, making them suitable for conditions that require quick relief.

Chronic Pain 52

Chronic Pain Topical Marijuana Indica 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

FloridaMarijuana.net

JUNE 22, 2018

Patients who suffer from this condition also face other symptoms that are painful, inconvenient -to say the least, -and lower their quality of life. Many of these medications have serious side effects that only add on to the stress, pain, and frustration that patients already feel due to their condition.

Hybrid 189

Hybrid Marijuana Sativa Nerve Pain 189

Canna Care Docs

OCTOBER 3, 2023

However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill. Depending on the type of terminal illness diagnosed by the doctor, there are numerous pharmaceutical and conventional medications provided for patients to treat the symptoms that come with a terminal illness.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

JULY 29, 2021

With Avicanna’s dedication to quality standards and pharmaceutical positioning we are poised to be a significant long-term player in the European medical market that is predominantly focused on medical utility of cannabinoids and where meeting EU pharmacopeia standards are essential.”.

Extraction 98

Extraction Supply Chain THC Research and Development 98

Cannabis Law Report

AUGUST 6, 2021

CBD, which is an abbreviation for Cannabidiol, is one of Cannabis’s primary components – one of its primary Cannabinoids. Cannabinoids are the naturally occurring compounds found in the Cannabis plant. There are over 480 different Cannabinoids in the Cannabis plant. It is non-psychoactive and has a multitude of health benefits.

CBD 105

CBD Wellness and Beauty Treatment Pharmaceutical 105

CannaMD

FEBRUARY 19, 2020

Post-traumatic stress disorder (PTSD) is a condition most often associated with military veterans, but it is not confined to wartime experiences. Medical Marijuana: More Effective Than Pharmaceuticals? To date, there is no pharmaceutical product targeted specifically for the treatment of PTSD.

CBD 92

CBD Pharmaceutical Research and Development Conditions 92

FloridaMarijuana.net

AUGUST 15, 2018

The endocannabinoid system consists of cannabinoid receptors all over the body. When the body is defensive against trauma, this system begins to fail, resulting in physical, mental and/or neurological conditions. This system enables a connection between body and mind, signaling to all other systems when something feels good or bad.

Chronic Pain 150

Chronic Pain Marijuana Patients Clinical Trials 150

Veriheal

MARCH 9, 2021

A team of researchers at Australia’s University of Queensland and at Botanix Pharmaceuticals Limited found, for the first time, that CBD is effective in killing Gram-negative bacteria which could mean that a new class of antibiotics can be developed for bacteria which is resistant to other forms of pharmaceutical medications. .

Research and Development 108

Research and Development Pharmaceutical Cannabinoids CBD 108

United Patients Group

MAY 17, 2023

Introduction Autism spectrum disorder (ASD) is a neurodevelopmental condition that affects communication, social interactions and behaviors. Some researchers believe that cannabinoids may help people with ASD manage anxiety and stress by increasing their ability to focus and pay attention.

Sleep 78

Sleep Cannabinoids Patients CBD 78

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

TheAnswerPage

MAY 20, 2022

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? GW Pharmaceuticals website. See the Answer.

Nerve Pain 52

Nerve Pain Epilepsy Pharmaceutical Cannabinoids 52

Cannabis Law Report

JULY 26, 2021

(OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., as an independent director to the Company’s board. About Skye Bioscience. Skye Bioscience Inc.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

It seems like the medical research community remains largely divided on the issue, with some insisting that cannabis use contributes to mental health condition diagnoses while others suggesting that people with mental health conditions are inherently drawn to cannabis use. CBD for Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

JUNE 19, 2021

Report authors ex-Tory leader Sir Iain Duncan-Smith and MPs George Freeman and Theresa Villiers highlight two problems with the existing hemp and cannabinoid licensing rules. Better inter-governmental co-operation must be beneficial as long as those involved understand that cannabis is a plant and not a pharmaceutical product.”.

Research and Development 105

Research and Development Cannabinoids Medicine Hemp 105